Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GOAL.MD vs Ivy Rx

GOAL.MD
Graded #142

Higher grade

vs+1.7999999999999972
Ivy Rx
Graded #178

Lower grade

The verdict

GOAL.MD takes it — 68.6/100 to 66.8/100, but only just.

GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing Ivy Rx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGOAL.MD +3
65
62
Dose & formulationGOAL.MD +22
86
64
Clinical oversightIvy Rx +14
68
82
Labs & monitoringEven
53
53
FulfillmentIvy Rx +4
77
81
Contract termsEven
55
55
GOAL.MD · left barIvy Rx · right bar

The numbers

MetricGOAL.MDIvy Rx
WeighScore68.6/10066.8/100
GradeCC
Scorecard rank#142#178
Semaglutide$179/mo$175/mo (starting dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)$275/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
GOAL.MD

Graded #142 · C

Strengths

  • Transparent dose-tiered pricing on brand pens
  • LegitScript Certified
  • Manual-renewal model — no surprise auto-billing
  • Free nutrition coach included
  • BBB A+ rating since 2021

Where it loses points

  • No named compounding pharmacy partner
  • Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
  • No URAC or PCAB pharmacy accreditation
Ivy Rx

Graded #178 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard